Special Issue "Recent Advancement in the Management of COVID-19"
Special Issue Editors
Interests: antimicrobial agents; antimicrobial coatings; active/intelligent packaging; biodegradable polymer; biomaterials
Special Issues and Collections in MDPI journals
Interests: food engineering; industrial biotechnology; biobased chemicals; nutraceuticals; waste valorisation; novel food processing technologies
Special Issues and Collections in MDPI journals
Special Issue Information
Dear Colleague,
The COVID-19 outbreak was declared a global pandemic by the WHO in early 2020, causing a major threat to public health worldwide, with 187 million cases and 4.00 million deaths to date. The symptoms of COVID-19 disease include fever, cough, shortness of breath, fatigue, a loss of taste and smell, and gastrointestinal issues. It is either asymptomatic or symptomatic with a high risk of acute respiratory distress syndrome (ARDS), devastating pneumonia with bilateral lung infiltrates, cytokine storm syndrome, shock, and death. The COVID-19 pandemic has created a global crisis in both public health as well as the economy, thus creating the need for rapid development in diagnosis, fast-paced vaccine development, and associated medical research using modern technologies. The various management strategies are functioning to overcome the COVID-19 pandemic. Thus, the aim of this Special Issue is to present innovative ideas and recent advances in the management of the COVID-19 pandemic, including diagnostics, current development in vaccine, and advancement in treatment strategies aside from vaccines.
In this Special Issue, we invite you to submit original research, review articles, and opinions in the broad area of COVID-19.
Dr. Swarna Jaiswal
Dr. Amit K. Jaiswal
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. COVID is an international peer-reviewed open access quarterly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- diagnostic methods
- vaccine development
- therapeutic
- immune response
- advancement in treatment
- pathogenesis
- immunotherapy
- epidemiology
- knowledge and practice